[1] Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
[2] Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10, 698-712.
[3] Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99.
[4] Timmers M, Van Broeck, B., Ramael, S., Slemmon, J., De Waepenaert, K., Russu, A., Bogert, J.M., Stieltjes, H., Shaw, L.M., Engelborghs, S., Moechars, D., Mercken, M., Liu, E., Sinha, V., Kemp, J., Van Nueten, L., Tritsmans, L., Streffer, J. R. (2016) Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2, 202-212.
[5] Timmers M, Streffer JR, Russu A, Tominaga Y, Shimizu H, Shiraishi A, et al. (2018) Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study. Alzheimers Res Ther 10, 85.
[6] Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5, 228-234.
[7] Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. (2014) Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 71, 1282-1289.
[8] FDA US. Guidance for industry drug-induced liver injury: premarketing clinical evaluation. US FDA, Silver Spring, MD, USA. 2009 Jul. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-induced-liver-injury-premarketing-clinical-evaluation. Accessed July 23, 2019.
[9] Struyfs H, Van Broeck B, Timmers M, Fransen E, Sleegers K, Van Broeckhoven C, et al. (2015) Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-beta Isoforms for Early and Differential Dementia Diagnosis. J Alzheimers Dis 45, 813-822.
[10] Van Broeck B, Borgers, M., Meulders, G., Hermans, B., Dhuyvetter, D., Borghys, H., Mercken, M. (2013) Simultaneous evaluation of AB1-37/38/40/42 levels after treatment with secretase inhibitors and modulators using a novel immunoassay. Neurodegener Dis 11.
[11] Prados F, Cardoso MJ, Leung KK, Cash DM, Modat M, Fox NC, et al. (2015) Measuring brain atrophy with a generalized formulation of the boundary shift integral. Neurobiol Aging 36 Suppl 1, S81-90.
[12] Rochin L, Hurbain I, Serneels L, Fort C, Watt B, Leblanc P, et al. (2013) BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc Natl Acad Sci U S A 110, 10658-10663.
[13] Brashear HR, Ketter N, Bogert J, Di J, Salloway SP, Sperling R (2018) Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies. J Alzheimers Dis 66, 1409-1424.
[14] Vannini P, Amariglio R, Hanseeuw B, Johnson KA, McLaren DG, Chhatwal J, et al. (2017) Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease. Neuropsychologia 99, 343-349.
[15] Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, et al. (2018) Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. N Engl J Med 378, 1691-1703.
[16] Selmi C, De Santis M, Gershwin ME (2011) Liver involvement in subjects with rheumatic disease. Arthritis Res Ther 13, 226.
[17] Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Romano G (2019) Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease. N Engl J Med 380, 1483-1485.
[18] Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, et al. (2019) Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. N Engl J Med 380, 1408-1420.
[19] Knopman DS (2019) Lowering of Amyloid-Beta by beta-Secretase Inhibitors - Some Informative Failures. N Engl J Med 380, 1476-1478.
[20] Barao S, Moechars D, Lichtenthaler SF, De Strooper B (2016) BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease. Trends Neurosci 39, 158-169.
[21] Ben Halima S, Mishra S, Raja KMP, Willem M, Baici A, Simons K, et al. (2016) Specific Inhibition of beta-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein. Cell Rep 14, 2127-2141.
[22] Piton M, Hirtz C, Desmetz C, Milhau J, Lajoix AD, Bennys K, et al. (2018) Alzheimer's Disease: Advances in Drug Development. J Alzheimers Dis 65, 3-13.
[23] Yan R (2016) Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs. Transl Neurodegener 5, 13.